Thin
1 / 1
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Deslorelin is a potent synthetic GnRH analog, approximately 30 to 150 times stronger than natural GnRH. It initially causes a temporary stimulation of gonadotropins before desensitizing pituitary GnRH receptors, which suppresses LH and FSH secretion and leads to the inhibition of sex steroid hormone production.
Deslorelin is widely approved for animal reproductive management, such as suppressing estrus in female dogs and modulating sexual behaviors in male horses. It is also utilized to treat hormone-related conditions like canine prostate disease and hyperadrenocorticism.
Yes, research has examined Deslorelin for hormone-dependent disorders such as precocious puberty, endometriosis, uterine fibroids, as well as adjuvant treatment for prostate and breast cancers, and pituitary downregulation during controlled ovarian stimulation.
Clinical progress in human medicine has largely stalled due to intense market competition from established alternatives like leuprorelin and goserelin, alongside patent-related constraints.
Future progress is primarily expected to stem from technological advancements in specialized delivery systems or targeted therapies, although significant short-term shifts in clinical adoption remain unlikely.
